Patents by Inventor Patrick Finn
Patrick Finn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10464962Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.Type: GrantFiled: October 7, 2016Date of Patent: November 5, 2019Assignee: GENZYME CORPORATIONInventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
-
Patent number: 10328218Abstract: A nebulizer system includes a body having a fluid chamber and an aerosol chamber, and a vibrator assembly positioned at an interface between the fluid chamber and the aerosol chamber. The vibrator assembly may include a diaphragm, having a fluid side and an aerosol side, defining a plurality of perforations between the fluid side and the aerosol side, and one or more vibrator elements operatively associated with the diaphragm to vibrate the diaphragm to produce aerosolized medicament projected into the aerosol chamber from the plurality of perforations. Each perforation of the plurality of perforations projects the aerosolized medicament along a respective projection path relative to a plane defined by the aerosol side of the perforation, the one or more vibrator elements or the diaphragm support substrate further being configured to angularly displace the aerosol side of the diaphragm to sweep the direction of at least one projection path.Type: GrantFiled: May 5, 2016Date of Patent: June 25, 2019Assignee: ENGINEERED MEDICAL SYSTEMS, INC.Inventors: George Ashford Reed, Jeffrey John Quinn, Brad Hayden Quinn, Patrick Finn Boileau
-
Publication number: 20190078084Abstract: The present disclosure relates to methods and kits for DNA library construction, particularly for consistent and reproducible DNA sequencing.Type: ApplicationFiled: April 4, 2018Publication date: March 14, 2019Applicant: ArcherDX, Inc.Inventors: Patrick Finn, Greg Patton, Hongbo Liu
-
Publication number: 20190062416Abstract: A method of treating primary focal segmental glomerulosclerosis in a patient having an APOL1 variant, comprising intravenously administering a TGF? antagonist to the patient.Type: ApplicationFiled: June 17, 2016Publication date: February 28, 2019Applicant: GENZYME CORPORATIONInventors: Steven R. Ledbetter, Sara Engstrand, Patrick Finn, Julie Lin, Robert John Pomponio
-
Publication number: 20180244763Abstract: The invention provides an improved pan-TGF-? antibody for treatment of conditions that are mediated by TGF-?, including autoimmune diseases, fibrotic conditions, and cancers. Also provided are methods and uses of the antibody in conjunction with other immunomodulatory agents such as an anti-PD-1 antibody.Type: ApplicationFiled: January 19, 2018Publication date: August 30, 2018Applicant: SANOFIInventors: Gary Shapiro, Kevin Brower, Patrick Finn, Richard C. Gregory, Rao Koduri, Feng Liu, Natalia Malkova, Parminder Mankoo, Jack R. Pollard, Huawei Qiu, Joachim Theilhaber, Christopher Winter, Marcella Yu
-
Patent number: 9861779Abstract: An improved oscillating positive expiratory pressure (“OPEP”) device, for respiratory therapy having a self sterilizing flow valve capable of insertion into the curved OPEP body without tools or aids. The flow valve is also tear resistant and incorporates a flared reinforced proximal end. To maximize the benefit to patients, the adjustable therapy selector is constrained from withdrawal and is dimensioned to accept commercially available, standardized respiratory fittings adaptors, mouthpieces and “Tees” that are capable of connection to multiple respiratory therapy devices or medicated aerosol delivery units. The aesthetics have been altered by the addition of an arced handle.Type: GrantFiled: June 21, 2016Date of Patent: January 9, 2018Inventors: George Ashford Reed, Patrick Finn Boileau
-
Publication number: 20180002365Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.Type: ApplicationFiled: October 7, 2016Publication date: January 4, 2018Inventors: Luis Z. AVILA, Clark Q. PAN, Patrick FINN, John HARRAHY, Qun ZHOU, Yunxiang ZHU, Paul A. KONOWICZ, Duncan E. PATERSON, Andreas PEER, Joseph P. KUTZKO, Michael R. REARDON, James E. STEFANO, Xiaoyang ZHENG, Robert J. MILLER, Lauren YOUNG
-
Publication number: 20170361056Abstract: An improved oscillating positive expiratory pressure (“OPEP”) device, for respiratory therapy having a self sterilizing flow valve capable of insertion into the curved OPEP body without tools or aids. The flow valve is also tear resistant and incorporates a flared reinforced proximal end. To maximize the benefit to patients, the adjustable therapy selector is constrained from withdrawal and is dimensioned to accept commercially available, standardized respiratory fittings adaptors, mouthpieces and “Tees” that are capable of connection to multiple respiratory therapy devices or medicated aerosol delivery units. The aesthetics have been altered by the addition of an arced handle.Type: ApplicationFiled: June 21, 2016Publication date: December 21, 2017Inventors: George Ashford Reed, Patrick Finn Boileau
-
Publication number: 20170106155Abstract: A nebulizer system includes a body having a fluid chamber and an aerosol chamber, and a vibrator assembly positioned at an interface between the fluid chamber and the aerosol chamber. The vibrator assembly may include a diaphragm, having a fluid side and an aerosol side, defining a plurality of perforations between the fluid side and the aerosol side, and one or more vibrator elements operatively associated with the diaphragm to vibrate the diaphragm to produce aerosolized medicament projected into the aerosol chamber from the plurality of perforations. Each perforation of the plurality of perforations projects the aerosolized medicament along a respective projection path relative to a plane defined by the aerosol side of the perforation, the one or more vibrator elements or the diaphragm support substrate further being configured to angularly displace the aerosol side of the diaphragm to sweep the direction of at least one projection path.Type: ApplicationFiled: May 5, 2016Publication date: April 20, 2017Inventors: George Ashford Reed, Jeffrey John Quinn, Brad Hayden Quinn, Patrick Finn Boileau
-
Patent number: 9493498Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.Type: GrantFiled: July 29, 2014Date of Patent: November 15, 2016Assignee: GENZYME CORPORATIONInventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
-
Patent number: 9352108Abstract: A nebulizer system includes a body having a fluid chamber and an aerosol chamber, and a vibrator assembly positioned at an interface between the fluid chamber and the aerosol chamber. The vibrator assembly may include a diaphragm, having a fluid side and an aerosol side, defining a plurality of perforations between the fluid side and the aerosol side, and one or more vibrator elements operatively associated with the diaphragm to vibrate the diaphragm to produce aerosolized medicament projected into the aerosol chamber from the plurality of perforations. Each perforation of the plurality of perforations projects the aerosolized medicament along a respective projection path substantially normal to a plane defined by the aerosol side of the perforation, the one or more vibrator elements further being configured to angularly displace the aerosol side of the diaphragm to sweep the direction of at least one projection path.Type: GrantFiled: October 15, 2015Date of Patent: May 31, 2016Inventors: George Ashford Reed, Jeffrey John Quinn, Brad Hayden Quinn, Patrick Finn Boileau
-
Publication number: 20160063449Abstract: A method is provided for scheduling a meeting. The method includes receiving a request from an organizer to schedule a meeting, executing a constraint satisfaction algorithm to determine at least one meeting data set comprising a value for at least one variable in a set of variables. The meeting data set defines at least one of a proposed time, room or participants for the meeting. Executing the constraint satisfaction algorithm involves performing a backtracking search within a solution domain to determine the meeting data set for the set of variables that satisfies a set of meeting constraints. If no meeting data set is determined, the set of variables and the solution domain can be revised. A next backtracking search can be performed to determine the meeting data set for the revised set of variables in the revised solution domain that satisfies one or more of the meeting constraints.Type: ApplicationFiled: August 28, 2014Publication date: March 3, 2016Inventors: Colin Duggan, Patrick Finn, James Wagstaff, Kevin Burke
-
Patent number: 9266834Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.Type: GrantFiled: July 2, 2014Date of Patent: February 23, 2016Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma SAInventors: Hassan Julien Imogai, Jose Maria Cid-Nunez, Jose Ignacio Andres-Gil, Andres Avelino Trabanco-Suarez, Julen Oyarzabal Santamarina, Frank Matthias Dautzenberg, Gregor James MacDonald, Shriley Elizabeth Pullan, Robert Johannes Lutjens, Guillaume Albert Jacques Duvey, Vanthea Nhem, Terry Patrick Finn, Gagik Melikyan
-
Publication number: 20150336930Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.Type: ApplicationFiled: August 4, 2015Publication date: November 26, 2015Inventors: JOSE MARIA CID-NUNEZ, ANDRES AVELINO TRABANCO-SUAREZ, GREGOR JAMES MACDONALD, GUILLAUME ALBERT JACQUES DUVEY, ROBERT JOHANNES LÜTJENS, TERRY PATRICK FINN
-
Publication number: 20150291953Abstract: The present disclosure relates to methods and kits for DNA library construction, particularly for consistent and reproducible DNA sequencing.Type: ApplicationFiled: November 4, 2013Publication date: October 15, 2015Inventors: Patrick Finn, Greg Patton, Hongbo Liu
-
Patent number: 9132122Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.Type: GrantFiled: March 14, 2013Date of Patent: September 15, 2015Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma SAInventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Robert Johannes Lütjens, Terry Patrick Finn
-
Patent number: 9114138Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.Type: GrantFiled: September 12, 2008Date of Patent: August 25, 2015Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma SAInventors: Jose Maria Cid-Nunez, Andres Avelino Trabanco-Suarez, Gregor James MacDonald, Guillaume Albert Jacques Duvey, Robert Johannes Lutjens, Terry Patrick Finn
-
Publication number: 20150175643Abstract: Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate.Type: ApplicationFiled: July 29, 2014Publication date: June 25, 2015Inventors: Luis Z. Avila, Clark Q. Pan, Patrick Finn, John Harrahy, Qun Zhou, Yunxiang Zhu, Paul A. Konowicz, Duncan E. Paterson, Andreas Peer, Joseph P. Kutzko, Michael R. Reardon, James E. Stefano, Xiaoyang Zheng, Robert J. Miller, Lauren Young
-
Publication number: 20140315903Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors—subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.Type: ApplicationFiled: July 2, 2014Publication date: October 23, 2014Inventors: HASSAN JULIEN IMOGAI, JOSE MARIA CID-NUNEZ, JOSE IGNACIO ANDRES-GIL, ANDRES AVELINO TRABANCO-SUAREZ, JULEN OYARZABAL SANTAMARINA, FRANK MATTHIAS DAUTZENBERG, GREGOR JAMES MACDONALD, SHRILEY ELIZABETH PULLAN, ROBERT JOHANNES LUTJENS, GUILLAUME ALBERT JACQUES DUVEY, VANTHEA NHEM, TERRY PATRICK FINN, GAGIK MELIKYAN
-
Patent number: 8841323Abstract: The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.Type: GrantFiled: March 15, 2007Date of Patent: September 23, 2014Assignees: Janssen Pharmaceuticals, Inc., Addex Pharma S.A.Inventors: Jose Maria Cid-Nunez, Jose Ignacio Andres-Gil, Andres Avelino Trabanco-Suarez, Julen Oyarzabal Santamarina, Frank Matthias Dautzenberg, Gregor James MacDonald, Shirley Elizabeth Pullan, Robert Johannes Lutjens, Guillaume Albert Jacques Duvey, Vanthea Nhem, Terry Patrick Finn, Gagik Melikyan, Vincent Mutel